<DOC>
	<DOC>NCT00359359</DOC>
	<brief_summary>The purpose of the study is to determine whether the study drug ZK 219477 (also known as SH Y03757A) combined with cisplatin, is effective in the treatment of small cell lung cancer in patients who did not receive prior treatment for their lung cancer</brief_summary>
	<brief_title>A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Smallcell lung cancer Stage of extensive disease Adequate function of major organs and systems Use of highly effective birth control methods in females of childbearing potential Prior chemotherapy for smallcell lung cancer Prior surgical resection or radiotherapy for SCLC within at least 3 to 4 weeks prior to inclusion and with the exception of radiation of brain metastases Superior vena cava syndrome or obstruction of any vital structure Untreated malignant hypercalcemia; Extensive disease amenable to radiation therapy; Symptomatic brain metastases requiring wholebrain irradiation Known allergy or hypersensitivity to platinumcontaining drugs Pregnancy or breastfeeding Use of any investigational drug within 4 weeks before start of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>